Alnylam Pharmaceuticals | ALNY - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
Arrowhead Research USD 312.77M 53.52M 2025-12
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Moderna USD 1.31B 571M 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 32.02B 615M 2025-09
PTC Therapeutics USD 286.94M 2.42B 2026-03
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 21.76B 530M 2025-09
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
Takeda JPY 4.85T 208B 2025-12
Tectonic Therapeutic USD 876K 115K 2024-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.99B 44M 2026-03
Xencor USD 187.75M 118.48M 2025-12